Current technologies for HER2 testing in breast cancer.

Area of Science:

• Oncology
• Molecular Diagnostics
• Biomarker Analysis

Background:

• Molecular techniques are crucial for breast cancer detection, prognosis, and treatment response prediction.
• HER2/neu status is a key predictor of sensitivity to targeted therapies like trastuzumab and lapatinib.
• Various methods exist for HER2 assessment, including protein, RNA, and DNA-based assays.

Purpose of the Study:

• To provide an overview of recent advancements in HER2 testing methodologies.
• To discuss the current landscape and challenges in HER2 status assessment for breast cancer.

Main Methods:

• Review of existing and emerging molecular techniques for HER2 testing.
• Analysis of comparative studies evaluating different HER2 assessment strategies.
• Discussion on protein-, RNA-, and DNA-based assays, including in situ hybridization (ISH) systems.

Main Results:

• Despite good correlation in studies, discrepancies persist among various HER2 testing techniques.
• No single method is universally accepted as the gold standard due to inherent advantages and disadvantages.
• Lack of consensus exists regarding the superiority of protein vs. gene-based tests, ISH probe systems, and automation levels.

Conclusions:

• The selection of a HER2 testing strategy is influenced by practical and economic considerations pending large clinical trials.
• Standardization, robust quality control, laboratory accreditation, and automation are vital for reliable HER2 testing.
• Future directions emphasize automated tissue processing and image analysis for improved HER2 interpretation.